drugset / Trial / NCT00687713

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

NCT00687713

Phase 2 Completed 200 enrolled National Institute on Drug Abuse (NIDA)
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 days prior to the start of signing consent.

Timeline

Start
2008-05
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupropion Small molecule 150 mg